Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
Alkermes (ALKS) Stock Price & Analysis
448 Followers
ALKS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.46 - $32.88
Previous Close$23.85
Volume2.41M
Average Volume (3M)1.98M
Market Cap
$4.04B
Enterprise Value$3.63B
Total Cash (Recent Filing)$773.49M
Total Debt (Recent Filing)$372.19M
Price to Earnings (P/E)11.5
Beta0.29
Next Earnings
May 01, 2024EPS Estimate
$0.6Last Dividend Ex-Date
Nov 16, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)2.07
Shares Outstanding167,076,133
10 Day Avg. Volume2,210,046
30 Day Avg. Volume1,976,099
Standard Deviation0.11
R-Squared0.06
Alpha-0.00460
Financial Highlights & Ratios
Price to Book (P/B)3.55
Price to Sales (P/S)2.40
Price to Cash Flow (P/CF)9.30
P/FCF Ratio10.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.18
Enterprise Value/Gross Profit2.58
Enterprise Value/Ebitda6.99
Forecast
1Y Price Target
$35.50Price Target Upside48.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Alkermes News
PremiumCompany Announcements
Alkermes Reveals Promising Phase 1b Study ResultsBulls Say, Bears Say
Bulls Say
Clinical DevelopmentALKS 2680 has shown a clear dose response in improving wakefulness with a favorable safety profile, positioning it as a strong candidate in the narcolepsy treatment landscape.
Product PerformanceLybalvi is on track to do close to $300M this year, surpassing the $400M peak sales expectation, highlighting the product's strong market acceptance and growth potential.
Strategic PartnershipsHarmony's decision to develop TPM-1116 underscores the importance of the OX2R agonist class, benefiting Alkermes by validating their approach to treating sleep/wake disorders.
Bears Say
Market CompetitionThe orexin program faces stiff competition, which could impact the company's market share and future revenue potential.
Product PerformanceSales for Risperdal Consta are declining, in line with expectations due to increased competition.
Revenue RisksThere's likely to be a meaningful hit to the $410M in annual Vivitrol revenues upon generic entrants in January 2027.
---
Ownership Overview
6.56% Insiders
33.89% Mutual Funds
32.23% Other Institutional Investors
27.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALKS FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was $20.46 and its highest was $32.88 in the past 12 months.
What is Alkermes’s market cap?
Currently, no data Available
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is May 01, 2024 which is in 8 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Feb 15, 2024. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.447 by -$0.227.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes pays a Notavailable dividend of $1.64 which represents an annual dividend yield of N/A. See more information on Alkermes dividends here
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is $0.6.
How many shares outstanding does Alkermes have?
Alkermes has 169,184,190 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of $0.22 in its last earnings report, missing expectations of $0.447. Following the earnings report the stock price went up 16.327%.
Which hedge fund is a major shareholder of Alkermes?
Among the largest hedge funds holding Alkermes’s share is PRIMECAP Management Co. It holds Alkermes’s shares valued at 99M.
---
Alkermes Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.50 (48.85% Upside)
$35.50 (48.85% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 346.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.43%
12-Months-Change
Fundamentals
Return on Equity
35.93%
Trailing 12-Months
Asset Growth
8.77%
Trailing 12-Months
Company Description
Alkermes
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
---
ALKS Company Deck
---
ALKS Earnings Call
Q4 2024
0:00 / 0:00
---
ALKS Revenue Breakdown
55.31% Product sales, net
44.69% Manufacturing and royalty revenues
<0.01% Research and development revenue
0.00% License revenue
---
ALKS Stock 12 Months Forecast
Average Price Target
$35.50
▲(48.85% Upside)
Technical Analysis
Best Analysts Covering ALKS
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
-0.35%
assigned a buy rating 14 days ago
Copying Akash Tewari's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of -0.35% per trade.
---